蛋白质组微阵列鉴定HBV相关肝细胞癌自身抗体诊断标志物
本研究用HuProt阵列筛选HBV相关肝病血清蛋白标志物,并在HCC聚焦阵列中验证。研究筛出547个差异表达蛋白,鉴定出针对肿瘤相关抗原的10种潜在自身抗体及APEX2、RCSD1、TP53组合标志物,该组合在验证队列中灵敏度61.9%、特异度81.7%,并在大样本队列中确认其诊断能力优于甲胎蛋白。
要点
- APEX2、RCSD1、TP53自身抗体组合可用于HBV相关HCC诊断
- 该组合在HCC聚焦阵列验证队列中灵敏度61.9%、特异度81.7%
- 大样本验证显示该组合诊断能力优于甲胎蛋白
核心结论
- APEX2、RCSD1和TP53标志物组合可用于HBV相关HCC的诊断,为临床实践提供科学依据。
研究设计与样本
- 研究采用HuProt蛋白质组微阵列筛选HBV相关肝病的候选血清蛋白标志物。
- 研究用HCC聚焦阵列验证差异标志物,并通过ELISA验证血清标志物水平。
- 研究设有筛选队列、HCC聚焦阵列验证队列和大样本验证队列。
主要发现
- 研究从HBV感染相关HCC中鉴定出547个差异表达蛋白。
- 研究鉴定出10种针对肿瘤相关抗原的潜在差异自身抗体。
- 候选标志物组合APEX2、RCSD1、TP53在HCC聚焦阵列验证队列中灵敏度为61.9%、特异度为81.7%。
- 大样本验证队列确认了该标志物组合的蛋白水平与诊断能力。
- 该标志物组合被发现在诊断上优于甲胎蛋白。
关键数值与推荐
- APEX2、RCSD1、TP53组合在HCC聚焦阵列验证队列中灵敏度61.9%、特异度81.7%。
- 筛选阶段从HBV感染相关HCC中鉴定出547个差异表达蛋白。
- 研究鉴定出10种针对肿瘤相关抗原的潜在差异自身抗体。
临床怎么用
- 可关注APEX2、RCSD1、TP53自身抗体组合作为HBV相关HCC的辅助诊断标志物。
- 该组合在大样本验证中诊断能力优于甲胎蛋白,提示其潜在的临床补充价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Hepatocellular carcinoma (HCC) has the highest mortality rate among malignant tumors worldwide. This study aimed to analyze the biological characteristics of serum proteins in hepatitis B (HBV)-related liver diseases, identify diagnostic biomarkers for HBV-infected HCC, and provide a scientific basis for its prevention and treatment. MATERIALS AND METHODS: We used HuProt arrays to identify candidate biomarkers for HBV-related liver diseases and verified the differential biomarkers by using an HCC-focused array. The biological characteristics of serum proteins were analyzed via bioinformatics. Serum biomarkers levels were validated by ELISA. RESULTS: We identified 547 differentially expressed proteins from HBV-infected HCC in a screening cohort. After analyzing the biological characteristics of serum proteins, we identified 10 potential differential autoantibodies against tumor-associated antigens (TAAbs) and a candidate biomarker panel (APEX2, RCSD1, and TP53) for the diagnosis of HBV-associated HCC with 61.9% sensitivity and 81.7% specificity in an HCC-focused array validation cohort. Finally, the protein levels and diagnostic capability of the biomarker panel were confirmed in a large-sample validation cohort, and this panel was found to be superior to alpha-fetoprotein, the standard hallmark for the diagnosis of HCC. CONCLUSION: The APEX2, RCSD1, and TP53 biomarker panels could be used for the diagnosis of HBV-associated HCC, providing a scientific basis for clinical practice.
引用
- Zhang J, Hao W, Liu X, et al. Proteome microarray identifies autoantibody biomarkers for diagnosis of hepatitis B-related hepatocellular carcinoma. Clin Chim Acta. 2023. PMID: 38123112. doi:10.1016/j.cca.2023.117727
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。